Systematic assessment of factors influencing preferences of Crohn's disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL)

Inflammatory Bowel Diseases

Volumn 18, Issue 8, 2012, Pages 1523-1530

  Vavricka, Stephan R ^a,b   Bentele, Nicoletta ^a   Scharl, Michael ^a   Rogler, Gerhard ^a   Zeitz, Jonas ^a   Frei, Pascal ^a   Straumann, Alex ^c   Binek, Janek ^d   Schoepfer, Alain M ^e   Fried, Michael ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b TRIEMLI HOSPITAL   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

adalimumab; anti TNF drugs; certolizumab pegol; Crohn's disease; infliximab; patient reported outcomes

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; INFLIXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AGED; COLON; CROHN DISEASE; DRUG EFFICACY; DRUG INDICATION; DRUG PREFERENCE; DRUG SAFETY; FEAR; FEMALE; HEALTH SURVEY; HUMAN; ILEUM; MAJOR CLINICAL STUDY; MALE; PATIENT DECISION MAKING; PATIENT PREFERENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; REVIEW; SYRINGE; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PATIENT PREFERENCE; POLYETHYLENE GLYCOLS; PROGNOSIS; PROSPECTIVE STUDIES; QUESTIONNAIRES; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84863987436     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21888     Document Type: Review

References (35)

1. Satsangi J, Morecroft J, Shah NB, et al. Genetics of inflammatory bowel disease: scientific and clinical implications. Best Pract Res Clin Gastroenterol. 2003; 17: 3-18.
2. Blumberg RS, Saubermann LJ, Strober W,. Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. Curr Opin Immunol. 1999; 11: 648-656.
3. Beutler B, Greenwald D, Hulmes JD, et al. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature. 1985; 316: 552-554.
4. Old LJ,. Tumour necrosis factor (TNF). Science. 1985; 230: 630-633.
5. Van Deventer SJ,. Tumour necrosis factor and Crohn's disease. Gut. 1997; 40: 443-448.
6. Derkx B, Taminiau J, Radema S, et al. Tumour-necrosis-factor antibody treatment in Crohn's disease. Lancet. 1993; 342: 173-174.
7. Ricciardelli I, Lindley KJ, Londei M, et al. Anti-tumor necrosis factor alpha therapy increases the number of FOXP3 regulatory T cells in children affected by Crohn's disease. Immunology. 2008; 125: 178-183.
8. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997; 337: 1029-1035.
9. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999; 340: 1398-1405.
10. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999; 117: 761-769.
11. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359: 1541-1549.
12. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006; 130: 323-333.
13. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance of Crohn's disease: results of the CLASSIC II trial. Gut. 2007; 56: 1232-1239.
14. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007; 132: 52-65.
15. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn's disease previously treated with infliximab: a randomised trial. Ann Intern Med. 2007; 146: 829-838.
16. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007; 357: 228-238.
17. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007; 357: 239-250.
18. Lichtenstein GR, Thomsen OO, Schreiber S, et al. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. Clin Gastroenterol Hepatol. 2010; 8: 600-609.
19. Pellisé F, Sell P,; EuroSpine Patient Line Task Force. Patient information and education with modern media: the Spine Society of Europe Patient Line. Eur Spine J. 2009; 18 (Suppl 3): 395-401.
20. Greenfield S, Kaplan SH, Ware JE Jr, et al. Patients' participation in medical care: effects on blood sugar control and quality of life in diabetes. J Gen Intern Med. 1988; 3: 448-457.
21. Guadagnoli E, Ward P,. Patient participation in decision-making. Soc Sci Med. 1998; 47: 329-339.
22. Silliman RA, Dukes KA, Sullivan LM, et al. Breast cancer care in older women: sources of information, social support, and emotional health outcomes. Cancer. 1998; 83: 706-711.
23. Street RL Jr, Voigt B,. Patient participation in deciding breast cancer treatment and subsequent quality of life. Med Decis Making. 1997; 17: 298-306.
24. Moyer A,. Psychosocial outcomes of breast-conserving surgery versus mastectomy: a meta-analytic review. Health Psychol. 1997; 16: 284-298.
25. Institute of Medicine: Crossing the Quality Chasm: A New Health Care System for the 21st Century. Washington, DC: National Academy Press; 2001.
26. Keating NL, Beth Landrum M, Arora NK, et al. Cancer patients' roles in treatment decisions: do characteristics of the decision influence roles? J Clin Oncol. 2010; 28: 4364-4370.
27. Pittet V, Juillerat P, Mottet C, et al. Cohort profile: the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS). Int J Epidemiol. 2008; 38: 922-931.
28. Nikolaus S, Schreiber S,. Review article: diagnostics of inflammatory bowel disease. Gastroenterology. 2007; 133: 1670-1689.
29. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005; 19 (Suppl A): 5-36.
30. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006; 55: 749-753.
31. Stange EF, Travis SPL, Vermeire S, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut. 2006; 55 (Suppl 1): i1-15.
32. Chilton F, Collett RA,. Treatment choices, preferences and decision-making by patients with rheumatoid arthritis. Musculoskeletal Care. 2008; 6: 1-14.
33. Williams EL, Edwards CJ,. Patient preferences in choosing anti-TNF thereapies-R1. Rheumatology (Oxford). 2006; 45: 1575-1576.
34. Martin RW, Head AJ, Rene J, et al. Patient decision-making related to antirheumatic drugs in rheumatoid arthritis: the importance of patient trust of physician. J Rheumatol. 2008; 35: 618-624.
35. Van den Bemt BJ, Van Lankveld WG,. How can we improve adherence to therapy by patients with rheumatoid arthritis? Nat Clin Pract Rheumatol. 2007; 3: 681.